Navigation Links
US Patent Granted for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors for the Treatment of Cancer and Neurodegenerative Indications
Date:5/19/2011

60;Thus, anti-angiogenic therapies are only partly effective – as they do not inhibit invasion.  Another limitation in treating gliomas is the presence of the blood-brain barrier.  Thus, for a therapeutic to be an effective treatment for glioma, it must target both angiogenesis and invasion, and must penetrate the blood-brain barrier.

Potential Therapeutic Use in HER2+ Breast Cancer with Brain Metastases:  Amplification of Her2 receptor tyrosine kinase ("Her2") appears to occur in 20%-30% of all breast cancers.  Antibody-directed therapy with trastuzumab, which targets the extracellular domain of Her2, has been efficacious to some degree.  However, resistance to trastuzumab is common and added complications of resistance include metastatic disease where approximately 60% develop resistance after a year.  An alternate therapy which also targets Her2 is needed.  Treatment with Hsp90 inhibitors appears to induce the degradation of the Her2 receptor, thereby providing an alternate means for treating Her2+ tumors.  In fact, in clinical studies, Hsp90 inhibitors have demonstrated activity – clinical partial or complete response to therapy – against Her2+ tumors.


'/>"/>
SOURCE NexGenix Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Patents Issued for ViewRay Technology
2. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
3. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
4. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
5. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
6. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
9. IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery
10. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
11. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... Authorization Application (MAA) to the European Medicines Agency ... AMG 416) for the treatment of secondary hyperparathyroidism ... (CKD) on hemodialysis therapy. If approved, etelcalcetide will ... administered intravenously. Etelcalcetide is a novel ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ... the "An Introduction to Medical Device Software: ... 2015)" conference to their offering. ... to the regulations and requirements that apply to ... interactive, using real life examples and state-of- the-art ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced ... (London, UK - November 16-17, 2015)" conference to ... modules concerning Pharmacovigilance are a major departure in terms ... Europe . The intention of the course is ... how they overlap and fit together and what Companies ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... 8 Novavax, Inc. (Nasdaq: NVAX ) ... Driscoll, Chief Financial Officer of Novavax will be presenting ... place on Friday, September 17, 2010 at 10:20am local ... Driscoll will provide a company overview, outline its competitive ...
... (Nasdaq: TRBN ) today announced that the ... early termination of the waiting period under the Hart-Scott-Rodino ... with respect to the planned acquisition of Trubion by ... on Aug. 12, 2010. Accordingly, the requirement under the ...
Cached Medicine Technology:Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 2Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 3Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 4
(Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
(Date:9/3/2015)... ... September 03, 2015 , ... Leading post-acute electronic medical ... will be joining the company’s executive leadership team as VP of Product and ... experience in healthcare product and project management. He has been with HealthWyse since ...
(Date:9/2/2015)... Colorado (PRWEB) , ... September 03, 2015 , ... ... its wellness services - two retreats geared towards kick-starting and inspiring wellness in the ... love being a part of developing a whole mind-body approach to fitness - we ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading producer ... leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ... in Boston. , Larry Renfro, CEO of Optum, will deliver the morning address. ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Bermuda, Dec. 4 The Board of Directors of Tyco International Ltd. ... cash dividend of $0.20 per common share. The dividend is payable ... 2009. , , ABOUT TYCO ... is a diversified, global company that provides vital products and services to ...
... In the wake of the findings of its ... its importance in elite physical performance, Nestle has,launched a ... athletes,engaged in different kinds of sports. The program will ... sports nutrition in the future, which,should lead to a ...
... calling for more studies into the practice of forcing ... showed that there have been very few rigorous investigations ... the latest Journal of Advanced Nursing , suggests ... to be in their thirties with a diagnosis of ...
... Stem cells derived from bone marrow may serve as ... epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile ... Blood , the official journal of the American Society ... characterized by extraordinarily fragile skin and blistering on touch, ...
... Method to Redirect the Specificity of Immune Cells and ... GAITHERSBURG, Md., Dec. 4 MaxCyte, ... scale, non-viral cell loading systems, announces that Joseph C. ... at MaxCyte, will give a presentation on a breakthrough ...
Cached Medicine News:Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 2Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 3Health News:Coerced medication used in psychiatric care despite lack of clinical evidence 2Health News:Coerced medication used in psychiatric care despite lack of clinical evidence 3Health News:Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder 2Health News:Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder 3Health News:MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... a critical component of pain relief, functional ... Lumbosacral Bracing System™ offers the practitioner multiple ... of immobilization, unparalled comfort, and the ability ... even if they gain or lose weight. ...
... Aspen® Cervical Collars were designed to optimize ... better patient outcomes. The structure of the ... restriction without producing painful pressure points that ... patient compliance. For the ultimate in comfort, ...
... This comfortable pre-fabricated orthosis is designed ... distal third humeral diaphyseal fractures. The ... circumferential soft tissue compression for optimal ... range-of- motion of both shoulder and ...
Medicine Products: